

TOX3 Antibody (Center)

Affinity Purified Rabbit Polyclonal Antibody (Pab)

Catalog # AP4814c

Product Information

Application	WB, IHC-P, FC, E
Primary Accession	O15405
Reactivity	Human, Mouse
Predicted	Rat, Bovine, Canine, Rabbit, Chicken
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Clone Names	RB24743
Calculated MW	63342
Antigen Region	214-242

Additional Information

Gene ID	27324
Other Names	TOX high mobility group box family member 3, CAG trinucleotide repeat-containing gene F9 protein, Trinucleotide repeat-containing gene 9 protein, TOX3, CAGF9, TNRC9
Target/Specificity	This TOX3 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 214-242 amino acids from the Central region of human TOX3.
Dilution	WB~~1:1000 IHC-P~~1:100~500 FC~~1:10~50 E~~Use at an assay dependent concentration.
Format	Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.
Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions	TOX3 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	TOX3
Synonyms	CAGF9, TNRC9

Function	Transcriptional coactivator of the p300/CBP-mediated transcription complex. Activates transactivation through cAMP response element (CRE) sites. Protects against cell death by inducing antiapoptotic and repressing pro-apoptotic transcripts. Stimulates transcription from the estrogen-responsive or BCL-2 promoters. Required for depolarization-induced transcription activation of the C-FOS promoter in neurons. Associates with chromatin to the estrogen- responsive C3 promoter region.
Cellular Location	Nucleus.
Tissue Location	Expressed mainly in epithelial cells. Expressed in the central nervous system (CNS), in the ileum and within the brain in the frontal and occipital lobe.


Background

TOX3 contains an HMG-box, indicating that it may be involved in bending and unwinding of DNA and alteration of chromatin structure. The C-terminus of the encoded protein is glutamine-rich due to CAG repeats in the coding sequence. A minor allele of this gene has been implicated in an elevated risk of breast cancer.


References

Wacholder, S., et al. N. Engl. J. Med. 362(11):986-993(2010)
 Odefrey, F., et al. Cancer Res. 70(4):1449-1458(2010)
 Couch, F.J., et al. Cancer Epidemiol. Biomarkers Prev. 18(11):3044-3048(2009)
 Stacey, S.N., et al. Nat. Genet. 39(7):865-869(2007)

Images




Western blot analysis of TOX3 Antibody (Center) (Cat. #AP4814c) in mouse stomach tissue lysates (35ug/lane). TOX3 (arrow) was detected using the purified Pab.




TOX3 Antibody (Center) (Cat. #AP4814c) IHC analysis in formalin fixed and paraffin embedded brain tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the TOX3 Antibody (Center) for immunohistochemistry. Clinical relevance has not been evaluated.


Western blot analysis of TOX3 Antibody (Center) Pab (Cat. #AP4814c) pre-incubated without(lane 1) and with(lane 2)



blocking peptide in MDA-MB453 cell line lysate. TOX3 Antibody (Center) (arrow) was detected using the purified Pab.



Western blot analysis of TOX3 Antibody (Center) Pab (Cat. #AP4814c) pre-incubated without(lane 1) and with(lane 2) blocking peptide in mouse lung tissue lysate. TOX3 Antibody (Center) (arrow) was detected using the purified Pab.



TOX3 Antibody (Center) (Cat. #AP4814c) flow cytometric analysis of WiDr cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

Citations

- [TOX3 protein expression is correlated with pathological characteristics in breast cancer.](#)

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.